This is a single-center, placebo-controlled, randomized, double-blind, dose-escalation study
to evaluate safety, tolerability, and PK of a single oral (PO) administration of PCO371 in
healthy adult males.
Caucasian and Japanese subjects will be randomized to receive either PCO371 or placebo.
- Healthy male volunteers aged 18 to 45 years.
- Caucasian(BMI 18-30 mg/kg2) or first generation japanese(BMI 18-25kg/m2)
- Able and willing to abide by the protocol
- Evidence of any medical condition that could affect renal, hepatic, or